Summary of risk management plan for Arsenic trioxide (arsenic trioxide) 1 mg/ml concentrate for solution for infusion

This is a summary of the risk management plan (RMP) for Arsenic trioxide 1 mg/ml concentrate for solution for infusion. The RMP details important risks of Arsenic trioxide how these risks can be minimised, and how more information will be obtained about Arsenic trioxide's risks and uncertainties (missing information).

Arsenic trioxide's 1 mg/ml concentrate for solution for infusion summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Arsenic trioxide should be used.

This summary of the RMP for Arsenic trioxide should be read in the context of all this information including the assessment report of the evaluation and its plain-language summary, all which is part of the European Public Assessment Report (EPAR).

Important new concerns or changes to the current ones will be included in updates of Arsenic trioxide's RMP.

I. The medicine and what it is used for

Arsenic trioxide 1 mg/ml concentrate for solution for infusion is authorised for:

- Newly diagnosed low-to-intermediate risk acute promyelocytic leukaemia (APL) (white blood cell count,≤10 x 10^3µl) in combination with all-trans-retinoic acid (ATRA)
- Relapsed/refractory acute promyelocytic leukaemia (APL)(Previous treatment should have included a retinoid and chemotherapy)

characterised by the presence of the t(15;17) translocation and/or the presence of the Pro-Myelocytic Leukaemia/Retinoic-Acid-Receptor-alpha (PML/RAR-alpha) gene. It contains arsenic trioxide as the active substance and it is given by intravenous infusion.

Further information about the evaluation of Arsenic trioxide’s benefits can be found in the EPAR, including in its plain-language summary, available on the EMA website, under the medicine’s webpage https://www.ema.europa.eu/en/medicines/human/EPAR/arsenic-trioxide-accord.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Arsenic trioxide 1 mg/ml concentrate for solution for infusion, together with measures to minimise such risks and the proposed studies for learning more about Arsenic trioxide 1 mg/ml concentrate for solution for infusion risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation* measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed so that immediate action can be taken as necessary. These measures constitute routine pharmacovigilance activities.

If important information that may affect the safe use of Arsenic trioxide is not yet available, it is listed under 'missing information' below.

II.A List of important risks and missing information

Important risks of Arsenic trioxide are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely administered. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Arsenic trioxide. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine);

List of important risks and missing information	
Important identified risks	• None
Important potential risks	• Carcinogenicity
Missing information	• Long-term safety

II.B Summary of important risks

The safety information in the proposed Product Information is aligned to the reference medicinal product.

Important potential risk: Carcinogenicity

Risk minimisation measures	Routine risk minimisation measures: SmPC section: *4.4* Special warnings and precautions for use *5.3* Preclinical safety data Labelling Section: 7. Other special warnings: Cytotoxic: handle with caution. Prescription only medicine

Missing information Long-term safety	
Risk minimisation measures	Routine risk minimisation measures: Prescription only medicine

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of <invented name

II.C.2 Other studies in post-authorisation development plan

There are no studies required for Arsenic trioxide